Financing channel feed – Endpoints News

Financing channel feed

Immune Regulation, taking two clinical programs to 'reset' the immune system, nets $53M+ Series B

5 years ago

Seattle-based Athira, aiming for tough Alzheimer's and Parkinson's targets, raises $204M for IPO

5 years ago

A longtime CytomX exec re-emerges at Synthekine, an $82M Stanford spinout

5 years ago

One month after $115M megaround, muscle disease-focused Dyne goes public with $233M IPO

5 years ago

Past a turning point, Finch scores $90M to complete the final stretch for oral microbiome therapy

5 years ago

Jim Broderick reels in a $100M Series B to explore a 'new and big' angle of immune regulation

5 years ago

Metacrine, a Rich Heyman biotech targeting NASH and other liver diseases, raises $85M from IPO

5 years ago

Versant teams up with Stanford gene editing experts on a $45M next-gen play — marrying CRISPR and AAV to fix sickle cell

5 years ago

Using AI to sequence fungi genomes for cancer treatments, Hexagon Bio nets $47M in Series A

5 years ago

ImCheck adds $7.1M to Series B, boosting development of gamma delta T cell programs

5 years ago

Thanks to a $77.5M Series B, Escient moves into the clinic with the first of its sensory receptor candidates

5 years ago

Keith Dionne's Casma lines up a $50M venture round to continue the preclinical work on a cellular recycling program

5 years ago

Andrew Hirsch lines up a chunk of equity in his new job as C4 spells out development plans in IPO

5 years ago

As China's tech giants catch onto biotech, Baidu plots $2B startup focused on diagnosis, AI drug discovery

5 years ago

Orasis Pharmaceuticals snags $30M to see its presbyopia treatment through to PhIII

5 years ago

Codiak files for an IPO, again, this time shooting for a nine-digit raise

5 years ago

Animal data in hand, Nessan Bermingham banks $91.5M for Atlas-backed RNA editing play

5 years ago

MiNA Therapeutics bags nearly $30M Series A to push activating mRNA tech through the clinic

5 years ago

Recursion nabs $239M and an up to $1B partnership with Bayer as AI race heats up

5 years ago

$1.6 billion liquid biopsy player Grail files IPO, revealing 2021 commercial plans and a Midas-sized $65M pay package for Hans Bishop

5 years ago

Upstart sets off on a clinical journey, looking to make a name for its 2nd-gen CB1 blockers

5 years ago

China biotech InxMed bags $19M Series A+ to develop PhI FAK inhibitor

5 years ago

New targeted therapy approaches win Rain Therapeutics $63M — designed to beat a quick path to approval

5 years ago

Crossover round? Check. Top team? Check. Taysha sails to an IPO with $100M initial ask

5 years ago

First page Previous page 91 92 939495 96 97 Next page Last page